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Introduction
Modern assisted reproductive technologies (ART) uti-
lize ovarian stimulation to increase the number of
available oocytes and the outcome. However, the use
of ovarian stimulation increases the patients’ cost and
suffering, and is associated with side effects including
ovarian hyperstimulation syndrome (OHSS) and poten-
tial cancer risk. The recovery of immature oocytes fol-
lowed by in vitro maturation (IVM) and fertilization is an
attractive alternative to in vitro fertilization (IVF). Because
few or no injections of gonadotropins are needed, IVM
reduces the patients’ cost and suffering and avoids the
side effects associated with ovarian stimulation.
Another application of IVM is preservation of
women’s fertility; for example, cancer patients who are
going to undergo cancer treatment [1]. Cryopreserva-
tion of immature oocytes or ovarian tissue, coupled
with IVM, is a potential way to preserve fertility [2].
Besides, immature oocytes can be a new source of
oocyte donation. Pregnancies resulting from immature
oocyte donation have been reported from oophorec-
tomy specimen [3], during cesarean section [4], and
from a woman with polycystic ovaries [5].
Oocyte Maturation
Oocyte maturation is a complex process that comprises
nuclear maturation and cytoplasmic maturation. After
birth, human oocytes remain at prophase I of meiosis
until they are stimulated by gonadotropin to resume
meiosis before ovulation. Nuclear maturation refers to the
resumption of meiosis and progression from germinal
vesicle breakdown (GVBD) to metaphase II (MII). Cyto-
plasmic maturation refers to the preparation of oocyte
cytoplasm for fertilization and embryonic development
[6]. GVBD is initiated by the preovulatory surge of
luteinizing hormone (LH). LH probably induces GVBD
by an indirect action mediated by cumulus cells. The
oocyte and the cumulus cells are coupled by gap junc-
tions. Inhibitory factors are transported from the
cumulus cells to the oocytes to maintain meiotic arrest
of the oocytes. Some evidence suggests cyclic adeno-
sine monophosphate as a potential inhibitor of meiotic
resumption [7,8]. It was speculated that LH causes dis-
sociation of the cumulus cells and the oocyte, thus ter-
minating the flow of the meiosis-inhibiting substances
into the oocyte [6]. It is also possible that LH induces
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the production of a GVBD-inducing signal in the cumu-
lus cells that is subsequently transferred to the oocyte
through the gap junctions [9]. Cytoplasmic matura-
tion involves complicated processes that prepare the
oocyte for activation, fertilization, and development.
During this process, RNA molecules, proteins, and
imprinted genes are accumulated in the cytoplasm to
regulate oocyte meiosis and development [10]. Insuffi-
cient cytoplasmic maturation will fail to promote male
pronucleus formation and increase chromosomal abnor-
malities after fertilization [11].
Human IVM
In 1935, Pincus and Enzmann found that the rabbit
oocytes, when liberated from Graffian follicles, would
undergo spontaneous meiotic maturation in vitro [12].
Edwards demonstrated in 1965 that human oocytes
removed from follicles could mature in medium supple-
mented with serum [13]. The first human birth resulting
from IVM was reported by Cha et al in 1991 [3]. They
obtained immature oocytes from oophorectomy speci-
men. After maturing in vitro, the oocytes were donated
to a woman of premature menopause, and a set of
triplets was born. In 1994, Trounson et al reported the
first birth from IVM in women with polycystic ovarian
syndrome (PCOS), where Trounson developed a special
aspiration needle for immature oocytes [14]. However,
the maturation rate of human IVM was about 30–50%
[3,13,15], which was much lower than those of other
species, and the pregnancies resulting from IVM were
limited. Besides, Trounson et al have shown that the 
in vitro matured human oocytes had reduced develop-
mental competence [16]. The poor outcome of human
IVM was thought to be at least partly due to abnor-
malities of cytoplasmic maturation in in vitro-matured
oocytes. Several treatment modalities have been pro-
posed to improve the outcome of human IVM.
FSH Priming
The early studies on human IVM did not use gonado-
tropin before oocyte retrieval. Since follicle-stimulating
hormone (FSH) acts on cumulus cells and promotes
steroid production, oocyte RNA and protein synthesis
[17], it has been postulated that pretreatment with
FSH might increase either the number of immature
oocytes recovered or the maturation potential and
developmental competence of the oocytes. It has been
shown in rhesus monkeys that after FSH priming for 6–7
days, greater percentages of oocytes completed meiotic
maturation (74% vs. 41%), fertilized (85% vs. 61%), and
cleaved from the 2–4 cell (79% vs. 38%) [18].
The effects of FSH priming on human IVM were
contradictory. Wynn et al gave a truncated course of
600 IU FSH to normal women; after which, a signifi-
cantly greater percentage of oocytes completed mei-
otic maturation in vitro (71.1% vs. 43.5%) and higher
serum E2 concentrations on the day of oocyte retrieval
were found after FSH treatment (1,049 ± 241 pg/mL
vs. 154 ± 17 pg/mL) [19]. Mikkelsen and Lindenberg
pretreated PCOS women with 150 IU FSH per day for
3 days and found that the maturation rate was signi-
ficantly higher in the FSH-primed group (59% vs. 44%),
although the fertilization rates and embryo cleavage
were not different between the two groups [20]. How-
ever, in their other similar study on normal cyclic
women, FSH priming did not make any difference in
the number of oocytes obtained, maturational poten-
tial and embryo development [21]. Similarly, Trounson
et al also found no significant differences in the num-
ber of oocytes recovered, maturation rate, fertilization
rate, and embryo development in patients pretreated
with recombinant FSH compared to patients without
treatment [16].
hCG Priming
Since LH surge or human chorionic gonadotropin (hCG)
injection induces final oocyte maturation, it is tempt-
ing to give hCG before oocyte retrieval in IVM cycles. In
1999, Chian et al reported a series of 25 IVM cycles in
PCOS women [22]. By giving 10,000 IU hCG 36 hours
before oocyte retrieval, they obtained an impressive
pregnancy rate of 40%. In their other randomized study
comparing the outcome of IVM with and without hCG
priming, the maturation process was faster in the hCG-
primed group [23]. The percentage of MII oocytes
after 48 hours of culture was higher in the hCG-primed
group (84.3%) than in the non-hCG-primed group
(69.1%), although the rates of fertilization and cleav-
age and embryo quality were similar between the two
groups.
We have performed a randomized study on PCOS
women to see if the combination of FSH priming and
hCG priming would improve the outcome of IVM.
Seventy-five IU rFSH was administered for 6 days in 
35 cycles while 33 cycles did not have rFSH admin-
istered; 10,000 IU hCG were given 36 hours before
oocyte retrieval. Serum estradiol level on the day of hCG
injection was significantly higher in the FSH-primed
group than in the non-FSH primed group (102.78 vs.
39.17 pg/mL), but the number of oocytes, endometrial
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thickness, and maturation, fertilization, and preg-
nancy rates were similar between the two groups [24].
From the above studies, we conclude that hCG 
priming plays a more important role in IVM, and FSH
priming has no additional beneficial effect.
Application of IVM
PCOS or PCO
The best candidates for IVM are women with PCOS 
or polycystic appearing ovaries (PCO) because these
women have many antral follicles. Tan et al demon-
strated that the pregnancy rates after IVM correlated
with the number of immature oocytes retrieved, with
the highest 26.8% in those with >10 immature oocytes
[25]. Child et al demonstrated that the number of
immature oocytes and pregnancy rates were higher 
in women with PCOS or PCO than in women with 
normal ovaries [26], and in PCOS women, IVM was
comparable to IVF [27].
High responders
Patients at risk of OHSS may also benefit from IVM. Lim
et al reported IVM in a series of patients undergoing
IVF who were at the risk of OHSS. hCG was adminis-
tered when the follicles reached 12–14 mm, and a preg-
nancy rate of 47.1% was obtained [28].
Poor responders
Other potential candidates of IVM are poor respon-
ders. Although several stimulation protocols and strate-
gies have been proposed for poor responders, some
women may still respond poorly to ovarian stimulation.
IVM may be an option for these women. Although the
outcome is still dismal for these women because only 
a few immature oocytes can be obtained (usually <5,
unpublished data and Chian RC, personal communi-
cation), at least they do not have to face the risk of
cycle cancellation after vigorous ovarian stimulation.
Liu et al reported three pregnancies out of eight patients
(37.5%), suggesting that IVM may be an alternative for
poor responders [29].
IVM in stimulated cycles
After ovarian stimulation with gonadotropin and hCG,
about 15% of oocytes are found in germinal vesicle (GV)
or metaphase I (MI) at the time of oocyte retrieval.
Attempts have been made to mature these oocytes 
in vitro but the results were very poor [30–33]. Recently
Chian et al designed a new IVM medium, which has
been shown to improve the maturation rate and blas-
tocyst development of GV oocytes from stimulated
cycles [34]. However, the GV oocytes obtained from
stimulated ovaries have a lower fertilization rate even
with intracytoplasmic sperm injection (ICSI) [35], and
the resulting embryos have high incidence of noncleav-
age (21%) and chromosomal anomalies (78.5%) [36].
We speculate that the oocytes that remain at the GV
stage in spite of ovarian stimulation are of inferior
quality or have intrinsic defects in the oocytes or folli-
cles. Further study is necessary to document the safety
of IVM with GV oocytes from stimulated cycles.
Combination of natural-cycle IVF and IVM
Recently, Chian et al proposed a combination of
natural-cycle IVF and IVM as a new approach in infertil-
ity treatment [37]. Ten thousand IU hCG were adminis-
tered when the largest follicle was 12–14 mm in natural
cycle. After oocyte retrieval 36 hours later, MII oocytes
were injected and GV oocytes were cultured in vitro,
which then underwent ICSI when they were MII. Similar
to natural-cycle IVF, this strategy is patient-friendly, but
may increase the number of embryos available.
Outcome of IVM
The results of IVM from several centers are listed in the
Table. The implantation rates of IVM are lower than IVF,
Table. Outcome of IVM from the literature
Authors No. of cycles
Maturation Fertilization Implantation Pregnancy
rate (%) rate (%) rate (%) rate (%)
Chian et al (2004) [37] 254 NA NA 11.1 24.0
Lim et al (2002) [28] 419 (day 3 transfer) NA NA 11.6 32.7
80 (day 5 transfer) 77.0 79.3 27.2 53.8
Lin et al (2003) [24] 68 74.2 88.8 10.5 33.8
Le Du et al (2005) [40] 42 63.1 70.1 10.9 20.0
Cha et al (2005) [38] 203 NA NA 5.5 20.2
NAnot available.
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but Lim et al reported a high implantation rate following
blastocyst transfer [28].
Among our 23 pregnancies, there were two miscar-
riages (8.7%), one stillbirth at 17 weeks, 10 preterm
deliveries (43.5%), and 10 term deliveries (43.5%). How-
ever, in the report of Cha et al, although there were 36.8%
miscarriage and 7.3% preterm labor, the obstetric out-
come of PCOS women treated by IVM was comparable
with those treated by IVF [38]. Mikkelsen reported 46
pregnancies with only two preterm deliveries and one
stillbirth [39].
We performed karyotyping in every case from amnio-
centesis or cord blood at delivery and all gave normal
results. There was no congenital anomaly and their
growth and development were all normal until 2 years
of follow-up. In the report of Cha et al, there were three
congenital anomalies out of 38 pregnancies (7.9%),
including hydrops fetalis, omphalocele, and cleft palate
[38]. Mikkelsen reported 47 children born after IVM in
whom chromosomal analysis was performed in 34 cases.
There was only one abnormal karyotype (46,XX, var(20)
cenh) but without clinical abnormalities. The only
baby with malformation is a girl with cleft palate [39].
From the available data of about 300 babies delivered
worldwide, IVM does not seem to increase the risk of
congenital anomalies [39,40].
Conclusion
Immature oocyte retrieval followed by IVM and fertil-
ization is now a feasible approach in ART. With or
without limited use of gonadotropin, IVM avoids the
side effects of ovarian stimulation and reduces the
patients’ expenses. This technique is better offered to
those women with many antral follicles, such as women
with PCOS or PCO. hCG priming initiates oocyte matu-
ration in vivo and produces favorable outcome in IVM.
The role of FSH priming is controversial.
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